Vicor's biggest risks are sequencing and value capture, not science. The core question is whether scarce
fab capacity, repeat licensing and customer diversification arrive before customers standardize around alternative or multi-sourced power architectures. Because the stock is already expensive, even solid execution may not be enough if
royalties stay lumpy or
Fab-2 slips.